Table 2.
Population Information in Dyslipidemia Subset
| GEMS | CoLaus | LOLIPOPW | CHS | FHS | EPIC | Fenland | ELY | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | 787 | 520 | 729 | 433 | 391 | 2258 | 748 | 208 | ||||||||
| Categorical variable, N (%) | ||||||||||||||||
| Men | 467 (59%) | 276 (53%) | 457 (63%) | 266 (61%) | 166 (42%) | 1018 (45%) | 328 (44%) | 98 (47%) | ||||||||
| Statins | 339 (43%) | 70 (14%) | 153 (21%) | 12 (3%) | 44 (2%) | 34 (5%) | 21 (10%) | |||||||||
| Continuous variable (N, Mean (SD)) | ||||||||||||||||
| Age, y | 775 | 49.2 (9.1) | 520 | 54.3 (10.1) | 729 | 52.7 (11.3) | 433 | 72.3 (5.3) | 391 | 61.6 (9.5) | 2258 | 59.4 (9.2) | 748 | 46.9 (7.2) | 208 | 61.5 (8.3) |
| Hypertension | ||||||||||||||||
| DBP, mm Hg | 771 | 81.7 (10.9) | 520 | 81.5 (11.5) | 729 | 81.4 (9.9) | 433 | 70.2 (10.9) | 391 | 75.2 (10.2) | 2256 | 84.7 (10.5) | 747 | 79.8 (9.8) | 208 | 82.1 (10.4) |
| SBP, mm Hg | 771 | 131.9 (17.3) | 520 | 131.9 (18.4) | 729 | 133.2 (19) | 433 | 136 (21.7) | 391 | 130.9 (18.1) | 2256 | 138.7 (17.6) | 747 | 127.3 (15.1) | 208 | 136.1 (17.4) |
| Inflammation | ||||||||||||||||
| Adiponectin, μg/mL | 743 | 5.5 (3.9) | 518 | 6.64 (4.57) | 329 | 6.58 (3.96) | 605 | 4.6 (2.2) | 95 | 6.0 (3.0) | ||||||
| CRPU, mg/L | 743 | 6 (10) | 520 | 3.7 (4.2) | 695 | 5.8 (6.6) | 1769 | 3.4 (3.9) | 605 | 4.1 (4.4) | 80 | 2.1 (2.3) | ||||
| Fibrinogen, g/L | 605 | 2.6 (0.62) | 431 | 3.27 (0.64) | 390 | 3.99 (0.76) | 2103 | 3.0 (0.8) | ||||||||
| IL‐1b, pg/mL | 603 | 47.9 (115) | 320 | 6.7 (20.3) | ||||||||||||
| IL‐6, pg/mL | 603 | 45 (72) | 496 | 18.4 (209.4) | 390 | 4.45 (4.43) | 43 | 1.5 (1.2) | ||||||||
| IL‐8, pg/mL | 603 | 38.2 (76.6) | 170 | 60.4 (281.3) | ||||||||||||
| Leptin, ng/mL | 685 | 16.1 (11.7) | 345 | 17.9 (12.3) | 605 | 25.4 (21.3) | 206 | 30.1 (26.7) | ||||||||
| MPO, ng/mL | 605 | 52 (104) | 311 | 49 (41) | 391 | 45.8 (31.7) | 352 | 102 (80) | ||||||||
| TNFA, pg/mL | 717 | 88 (132) | 512 | 5.7 (9.9) | 305 | 145.5 (120.5) | ||||||||||
| Insulin sensitivity | ||||||||||||||||
| 2h glucose, mmol/L | 45 | 6.9 (3.8) | 138 | 8.7 (3.5) | 728 | 6.2 (1.9) | 190 | 7.9 (2.9) | ||||||||
| Glucose, mmol/L | 683 | 5.2 (0.6) | 520 | 6.1 (1.9) | 729 | 6.2 (2.6) | 433 | 130 (52.2) | 384 | 6.7 (2.4) | 746 | 5.1 (0.6) | 208 | 5.4 (1) | ||
| HOMA‐B | 497 | 114.8 (88.2) | 700 | 175.2 (155.7) | 378 | 169.5 (128.1) | 738 | 166.8 (99.5) | 206 | 164.7 (88.9) | ||||||
| HOMA‐IR | 651 | 3.1 (2.5) | 497 | 3.8 (4.7) | 700 | 5.3 (8) | 378 | 6.96 (6.44) | 738 | 2.9 (2) | 206 | 3.5 (2.1) | ||||
| Insulin, mIU/mL | 743 | 12.9 (9.6) | 497 | 13.1 (8.8) | 700 | 17.9 (17.9) | 428 | 27.9 (42.4) | 378 | 22.19 (16.8) | 740 | 10.7 (6.4) | 206 | 12.1 (6.2) | ||
| Kidney function | ||||||||||||||||
| Creatinine, μmol/L | 520 | 81.9 (22) | 729 | 92.4 (27.3) | 433 | 1.18 (0.40) | 1770 | 84.4 (19.3) | 743 | 77.6 (15.2) | 97 | 88.0 (17.0) | ||||
| CRU, mmol/day | 504 | 14 108 (7139) | 743 | 11.9 (8.1) | ||||||||||||
| GFR | 520 | 77.8 (16) | 729 | 103.1 (32.1) | 391 | 80.6 (20.8) | 1770 | 77.8 (22.9) | 743 | 87.2 (16.4) | ||||||
| MACR | 504 | 2231 (6959) | 603 | 1.4 (2.9) | ||||||||||||
| MALB | 504 | 27.5 (72.1) | 603 | 16.4 (30.3) | ||||||||||||
| Lipid | ||||||||||||||||
| APOB, g/L | 743 | 1.2 (0.3) | 515 | 1.97 (1.63) | 1752 | 1.05 (0.3) | 605 | 1.1 (0.2) | ||||||||
| CHOL, mmol/L | 775 | 5.7 (1.2) | 520 | 5.8 (1.1) | 729 | 5.5 (1.1) | 433 | 206.0 (37.8) | 391 | 5.26 (1.04) | 2258 | 6.5 (1.1) | 748 | 5.7 (1) | ||
| HDL, mmol/L | 775 | 0.9 (0.2) | 520 | 1.1 (0.2) | 729 | 1 (0.1) | 433 | 35.0 (4.6) | 391 | 0.9 (0.2) | 2258 | 1.0 (0.2) | 748 | 1.1 (0.2) | 208 | 1.0 (0.2) |
| LDL, mmol/L | 618 | 3.4 (1.1) | 479 | 3.6 (1.0) | 639 | 3.2 (0.9) | 392 | 3.2 (0.98) | 355 | 3.0 (0.97) | 2258 | 4.2 (1.1) | 709 | 3.6 (0.9) | 206 | 3.7 (1) |
| TRIG, mmol/L | 775 | 3.5 (2.2) | 520 | 2.8 (2.1) | 729 | 3.1 (1.9) | 433 | 3.03 (1.44) | 391 | 3.06 (1.45) | 2258 | 3.0 (0.8) | 748 | 2.3 (1) | 208 | 2.8 (1.0) |
| Liver function | ||||||||||||||||
| ALB, g/L | 520 | 43.8 (2.6) | 729 | 43.2 (2.7) | 1784 | 41.8 (5.8) | 748 | 41.6 (2.7) | 97 | 42.2 (3.3) | ||||||
| ALP, U/L | 520 | 69.2 (21.1) | 727 | 84.8 (37.4) | 1789 | 64.6 (20.6) | 747 | 85.2 (22.1) | ||||||||
| ALT, U/L | 520 | 34 (21.6) | 729 | 34.3 (25.2) | 748 | 34.9 (19.4) | ||||||||||
| GGT, U/L | 520 | 39.1 (46.4) | 729 | 56.6 (116.6) | 1793 | 38.1 (30.9) | 748 | 41.3 (28.8) | ||||||||
| Obesity | ||||||||||||||||
| BMI, kg/m2 | 775 | 28.7 (3.6) | 520 | 29.1 (4.7) | 729 | 31 (5.6) | 433 | 28.2 (4.4) | 391 | 30.5 (5.3) | 2254 | 28.2 (3.9) | 687 | 30.6 (5.4) | 208 | 29.7 (4.6) |
| Body fat, % | 515 | 32.3 (9.7) | 690 | 35.6 (8.8) | 1412 | 35.8 (11.8) | 677 | 35.1 (9) | 205 | 36.1 (8.9) | ||||||
| Hip, cm | 764 | 108 (8.1) | 520 | 106.6 (9.7) | 728 | 108.2 (10) | 430 | 104 (9.2) | 384 | 108 (10.8) | 686 | 109.7 (10.6) | 205 | 109.8 (10) | ||
| Waist, cm | 765 | 98.3 (10.6) | 520 | 98.2 (12.5) | 728 | 104.5 (13.3) | 430 | 100.3 (11.3) | 384 | 105.9 (12.5) | 2257 | 93.8 (11.5) | 687 | 100.6 (12.9) | 206 | 99.5 (11.4) |
| Weight, kg | 775 | 84.7 (13.6) | 520 | 82.5 (15.5) | 729 | 90.4 (18) | 433 | 174 (30.4) | 391 | 84.7 (17.3) | 687 | 88.6 (17.8) | 208 | 82.3 (13.8) | ||
| Waist/hip ratio | 520 | 0.9 (0.1) | 727 | 1 (0.1) | 430 | 0.96 (0.07) | 383 | 0.98 (0.068) | 2252 | 0.89 (0.09) | 686 | 0.92 (0.08) | 205 | 0.91 (0.1) | ||
| Others | ||||||||||||||||
| Calcium, mmol/L | 520 | 2.2 (0.1) | 729 | 2.3 (0.1) | 747 | 2.2 (0.1) | 97 | 2.1 (0.1) | ||||||||
| URIC, μmol/L | 520 | 353.7 (91.5) | 726 | 340.6 (86.4) | 433 | 386.6 (95.2) | 1773 | 314.5 (83.6) | ||||||||
ALB indicates albumin ; ALP, alkaline phosphatase; ALT, alanine aminotransferase; CHS, Cardiovascular Health Study; CHOL, cholesterol; CoLaus, ; CRPU, ultrasensitive C‐reactive protein; CRU, urinary creatinine; APOB, apolipoprotein B; BMI, body mass index; CRP, C‐reactive protein; DBP, diastolic blood pressure; EPIC, European Prospective Investigation of Cancer; FHS, Framingham Heart Study; GEMS, Genetic Epidemiology of Metabolic Syndrome Study; GFR, glomerular filtration rate; GGT, γ‐glutamyl transferase; HDL, high‐density lipoprotein; HOMA‐B, homeostatic model assessment – beta‐cell; HOMA‐IR, homeostatic model assessment – insulin resistance; IL, interleukin; LDL, low‐density lipoprotein; LOLIPOPW, London Life Sciences Prospective Population Study – Whites; MACR, microalbumin‐creatinine ratio; MALB, microalbuminuria; MPO, myeloperoxidase; SBP, systolic blood pressure; TNFA, tumor necrosis factor α; TRIG, triglycerides; URIC, uric acid.